Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep377 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2017

The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis and visceral adipose tissue dysfunction in a rabbit model of high fat diet-induced metabolic syndrome

Comeglio Paolo , Cellai Ilaria , Filippi Sandra , Morelli Annamaria , Sarchielli Erica , Adorini Luciano , Maggi Mario , Vignozzi Linda

The nuclear Farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor 1 (TGR5) are bile acids receptors that play a key role in energy metabolism. In an animal model of non-genomic metabolic syndrome (MetS), obtained with a high fat diet (HFD), treatment with the dual FXR/TGR5 agonist INT767 reduced visceral adipose tissue (VAT) accumulation, insulin resistance, hypercholesterolemia and nonalcoholic steatohepatitis (NASH). In liver, INT767 reduced the high macrop...

ea0014p623 | (1) | ECE2007

Differential effects of two-week treatment with atorvastatin or elocalcitol, two RhoA/ROK signalling modulators, on erectile function and sildenafil responsiveness in spontaneously hypertensive rats

Morelli Annamaria , Zhang Xin-Hua , Filippi Sandra , Vignozzi Linda , Mungai Sara , Adorini Luciano

Increased RhoA/Rho-kinase (ROK) signalling is known to impair erectile function. Spontaneously hypertensive rats (SHR) over-express penile RhoA and show an impaired erectile response. We tested treatments known to inhibit RhoA activation, on erectile function and sildenafil responsiveness in SHR. SHR have been treated for two weeks with atorvastatin (5 and 30 mg/Kg/day), or with elocalcitol (30 μg/Kg/day), a vitamin D receptor (VDR) agonist. The normotensive Wistar Kyoto ...

ea0011p746 | Steroids | ECE2006

BXL-628, a vitamin D analog, decreases RhoA/ROK signalling in rat and human bladder

Morelli A , Filippi S , Mancina R , Vignozzi L , Vannelli GB , Ambrosini S , Crescioli C , Donati S , Adorini L , Maggi M

BXL-628 is a non-hypercalcemic calcitriol analog successfully tested in a phase IIa trial for benign prostate hyperplasia therapy. Because part of low urinary tract symptoms (LUTS) are generated by overactive bladder (OAB) and bladder expresses the calcitriol receptor (VDR), we investigated the BXL-628 effects on bladder contractility and RhoA/ROK signalling activated in OAB, by in vivo (2-weeks; 30 mcg/Kg, Sprague-Dawley, SD, and spontaneously hypertensive rats, SHR) a...

ea0041gp56 | Cardiovascular endocrinology | ECE2016

The dual FXR/TGR5 agonist INT-767 reduces visceral fat mass, promoting preadipocyte brown differentiation, mitochondrial function and insulin sensitivity in a rabbit model of high fat diet-induced metabolic syndrome

Vignozzi Linda , Cellai Ilaria , Filippi Sandra , Comeglio Paolo , Mello Tommaso , Bani Daniele , Guasti Daniele , Sarchielli Erica , Morelli Annamaria , Maneschi Elena , Vannelli Gabriella Barbara , Adorini Luciano , Maggi Mario

Expanding brown adipose tissue is a potential therapeutic strategy to counteract insulin resistance and metabolic syndrome (MetS). Farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) activation enhances insulin sensitivity, suggesting the capacity of FXR/TGR5 agonists to promote brown differentiation in adipose tissue. Treatment with increasing doses of the dual FXR/TGR5 agonist INT-767 (3, 10, 30 mg/Kg bw, daily for 5 days a week, by oral gavage, for 12 ...

ea0041ep201 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2016

The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis in a rabbit model of high fat diet-induced metabolic syndrome

Vignozzi Linda , Cellai Ilaria , Filippi Sandra , Comeglio Paolo , Sarchielli Erica , Morelli Annamaria , Maneschi Elena , Vannelli Gabriella Barbara , Adorini Luciano , Maggi Mario

Farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) are interesting pharmacological targets for the treatment of liver and metabolic diseases. FXR-deficient mice on a high-fat diet (HFD) exhibit massive hepatic steatosis, necro-inflammation and fibrogenesis. Moreover, pharmacological activation of TGR5 in mice promotes protective mechanisms in biliary epithelial cells and inhibits hepatic and systemic inflammation. Thus, we hypothesized that a FXR/TGR5 du...

ea0035p696 | Male reproduction | ECE2014

Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit

Vignozzi Linda , Filippi Sandra , Comeglio Paolo , Cellai Ilaria , Rastrelli Giulia , Morelli Annamaria , Galli Andrea , Saad Farid , Mannucci Edoardo , Adorini Luciano , Maggi Mario

A pathogenic link between erectile dysfunction (ED) and metabolic syndrome (MetS) is now well established. Nonalcoholic steatohepatitis (NASH), the hepatic hallmark of MetS, is regarded as an active player in the pathogenesis of MetS-associated cardiovascular disease (CVD). This study was aimed at evaluating the relationship between MetS-induced NASH and penile dysfunction. We used a non-genomic, high fat diet (HFD)-induced, rabbit model of MetS, and treated HFD rabbits with t...

ea0032p738 | Obesity | ECE2013

The FXR agonist obeticholic acid normalizes lipid droplet and triglyceride handling in visceral adipose tissue preadipocytes from a non-genomic rabbit model of metabolic syndrome

Maneschi Elena , Vignozzi Linda , Morelli Annamaria , Mello Tommaso , Filippi Sandra , Cellai Ilaria , Comeglio Paolo , Sarchielli Erica , Calcagno Alessandra , Vettor Roberto , Vannelli Gabriella Barbara , Adorini Luciano , Maggi Mario

Liver and visceral ectopic fatty tissue disposition is a major metabolic derangement leading to type 2 diabetes, hypertension, dyslipidaemia, recapitulated in the metabolic syndrome (MetS). We have demonstrated that the selective FXR agonist obeticholic acid (OCA, INT-747) ameliorates the metabolic profile and reduces visceral adipose tissue (VAT) in a high-fat diet (HFD)-induced rabbit model of MetS. We now report the effects of OCA treatment in HFD (0.5% cholesterol and 4% p...

ea0029p1045 | Male Reproduction | ICEECE2012

Elevated body mass index correlates with higher seminal interleukin 8 levels and ultrasound prostate abnormalities in infertile men

Maggi M. , Lotti F. , Corona G. , Colpi G. , Filimberti E. , Degli Innocenti S. , Mancini M. , Baldi E. , Noci I. , Adorini L. , Forti G.

Introduction: It is general acknowledgement that obesity is associated with a systemic, low-grade inflammatory state. Although the relationship between obesity and semen parameters or prostate diseases has been previously investigated, the association between body mass index (BMI), prostate inflammatory diseases and colour-Doppler ultrasound (CDU) features of the male genital tract (MGT) has been poorly studied. This study was aimed at evaluating the association between BMI an...

ea0029p1046 | Male Reproduction | ICEECE2012

Ultrasonographic and clinical correlates of seminal plasma interleukin 8 levels in patients attending an Andrology Clinic for infertility

Maggi M. , Lotti F. , Corona G. , Mancini M. , Filimberti E. , Degli Innocenti S. , Colpi G. , Baldi E. , Noci I. , Adorini L. , Forti G.

Introduction: Interleukin 8 (IL8) is a proinflammatory cytokine highly expressed in seminal plasma. Seminal IL8 (sIL8) has been proposed as a reliable surrogate marker of prostatitis and as a potential marker of male accessory gland infection (MAGI). So far, no study systematically evaluated the correlations of sIL8 with colour-Doppler ultrasound (CDU) features of the male genital tract. Hence, we investigated these possible correlations in infertile patients with MAGI.<p ...

ea0016p672 | Steroid receptors | ECE2008

The vitamin D receptor agonist elocalcitol up-regulates L-type Ca2+ channel activity in human and rat bladder

Morelli Annamaria , Squecco Roberta , Francini Fabio , Failli Paola , Filippi Sandra , Chavalmane Aravinda , Fibbi Benedetta , Mancina Rosa , Vignozzi Linda , Silvestrini Enrico , Gacci Mauro , Colli Enrico , Adorini Luciano , Maggi Mario

Human bladder contraction mainly depends on Ca2+ influx, via L-type voltage-gated Ca2+ channels, and on RhoA/Rho-kinase contractile signalling, a pathway up-regulated in overactive bladder (OAB) syndrome. Elocalcitol (Elo) is a vitamin D receptor agonist inhibiting RhoA/Rho-kinase signalling in rat and human bladder, shown to ameliorate OAB symptoms in a clinical study. Since in normal bladder from Sprague–Dawley (SD) rats Elo treatment delayed the c...